John Patterson, AstraZeneca Executive Director, Development, was recently interviewed by Pharmafocus, where he spoke about the rigorous work that has been put into simultaneously improving the quality, cost and speed of AstraZeneca's drug development process. "As with any big organisation, change takes time and we are now beginning to see some of the changes we have made take effect", said Patterson. In this article he also talks about the importance of having a good balance of first-in-class and best-in-class agents in the pipeline, the importance of translational medicine and biomarkers, the integration of MedImmune, etc.

Read the full article on Pharmafocus